Answers are grounded in this paper and cite their sources.
Therapeutic hypothermia (TH) has become the standard treatment for newborn infants suffering from moderate to severe hypoxic–ischaemic neonatal encephalopathy (HIE). Meta-analysis of the randomised controlled cooling trials has shown that TH significantly improves neurodevelopmental outcome at 18–24 months. Although there were some differences in the method of cooling, all trials recruited patients following strict entry criteria. Many infants were excluded because of concerns regarding potential adverse effects and efficacy, including preterm infants, growth-restricted infants, infants with congenial malformations and infants who could not be cooled down by 6 h of age. As TH becomes more widely used, many centres are cooling infants that would have been unable to receive this novel therapy through one of the randomised control trials. The lack of other proven neuroprotective interventions has created substantial pressure to offer TH and perhaps to broaden the selection criteria beyond those used in the trials. This editorial reviews several clinical situations where cooling may be considered for neuroprotection. The study by Smit et al. in this issue of Acta Paediatrica is a welcome addition to the subject 1. The incidence of moderate to severe HIE in preterm infants of 33–35 weeks' gestation is reported to be five in every 1000 live births, which is higher than the one to two per 1000 reported in term babies 2. The obvious question is whether or not induced TH is protective in the very immature brain, while there is some evidence that preterm infants may be particularly vulnerable to adverse systemic effects even during mild systemic hypothermia. The characteristic pattern of injury differs in preterm infants compared with term infants, with a much higher rate of selective damage to the periventricular white matter. More recently, it has become apparent from imaging and post-mortem studies that there is also an appreciable incidence of acute neuronal cell injury, mainly in subcortical nuclei 3. Preterm neural injury is a multifactorial disorder that may be associated with both antenatal and post-natal events, including systemic inflammation, as well as exposure to hypoxia–ischaemia. Although it is more difficult to clinically assess encephalopathy in very low birthweight infants, older premature infants of 31–36 weeks' gestation, who have metabolic acidosis on cord blood, show evolving clinical encephalopathy after birth, which, in turn, is associated with adverse neurological outcome 4. Two of the randomised controlled trials of TH included infants with a gestational age of 35 weeks or more 5. Several case reports and data from national registers confirm the safety and effectiveness of TH in late preterm infants. However, until trial results become available, TH cannot, and should not, be extrapolated to all preterm infants. In my opinion, it would not be reasonable to offer cooling for infants before 33 weeks' gestation. Experimental and human data strongly support the fact that hypothermia is neuroprotective in term infants if initiated within the first 6 h after birth, before the secondary deterioration phase. Such a short window does not allow us to apply this treatment to all neonates who might benefit from it. In the cooling trials, hypothermia was initiated at a median age of approximately 4 h with little variability among the trials. No interaction effects were seen between the age at initiation of cooling and outcome within this window, but the trend favoured earlier cooling 6. It remains unclear why there is a relatively protracted period between delivery and time to initiation of TH given that high-risk infants can often be initially identified as early as in the delivery room. Data from the French Register indicated that the late initiation of TH was the result of a long delay of nearly 8 h between admission and treatment time. This delay was most likely secondary to the clinical and/or electrophysiological assessment of the newborn infant before starting hypothermia 7. Broader utilisation of amplitude-integrated electroencephalography, which is simple to implement and interpret, should make it easier to obtain objective and earlier assessments of the neurological prognosis and to select infants that could benefit from TH. Because many infants are not born in referral hospitals, training and education should focus on early identification of neonates at high risk of evolving brain injury and on prompt passive cooling. In the case of inadvertent delay, it seems reasonable to start cooling in infants six to 12 h after birth, given that the possible neurological benefits would outweigh the small risks of hypothermia. A randomised controlled trial is currently assessing late-onset TH in infants with post-natal ages of between six and 24 h (Clinical Trial Identifier NCT00614744). An alternative strategy would be to extend the window of intervention of hypothermia. Although this field is still young, strategies for extending the window of opportunity are being tested in experimental models. No specific neuroprotective interventions are currently available for managing acute perinatal stroke. Most neonates with arterial ischaemic stroke present with focal seizures at 12 or more hours of age and are often in good condition at birth. However, encephalopathy can be a presenting feature of perinatal stroke, which may initially lead to a diagnosis of birth asphyxia. Approximately 3–5% of neonates who present with HIE are found to have focal infarcts on neuroimaging 8. Neonates with stroke who present with encephalopathy tend to have significantly poorer outcome. Recent evidence suggests that hypothermia is associated with a decrease in seizures in newborns with HIE and arterial ischaemic stroke 9. This association was not observed in the control group who did not receive TH. For an infant cooled because of suspected HIE, and where a revised diagnosis of stroke is made, it seems reasonable to continue cooling in the absence of intracranial bleeding. No randomised trials are investigating the effect of TH in newborn infants with arterial ischaemic stroke, and this means that definite evidence of benefit is lacking. There have been multiple trials with induced hypothermia following stroke in adults. Reductions in mortality rates or improvements in neurological outcome were not observed consistently across studies. Sudden unexpected post-natal collapse of apparently healthy infants in the maternity ward within the first day of life has received increased attention. Even if this is considered rare, the consequences are grave, with death reported in 33–50% of cases and permanent neurological disability in the majority of the surviving infants. Main risk factors include unsupervised skin-to-skin contact and/or first breastfeeding attempts, prone asphyxiating position, primiparity and distractions or lack of surveillance in the delivery room. Although no randomised trial has investigated the effect of TH in newborn infants following early post-natal collapse, these babies often have evidence of hypoxic–ischaemic brain injuries on magnetic resonance imaging and so are likely to benefit from TH. Preliminary and encouraging results have been reported by several observational studies in newborn infants with sudden unexpected post-natal collapse that underwent cooling. So far, there is a lack of data about other possible indications of TH. Novel uses of hypothermia have been suggested for advanced necrotising enterocolitis or as adjunct treatment in hyperammonaemia and metabolic encephalopathy 10. Additional research of the efficacy and safety of TH in conditions outside HIE is warranted. Carefully designed safety studies and large cooling randomised controlled trials for these novel indications should be considered. As TH enters routine practice, it is anticipated that there will be a significant drift between the conditions of implementation of this therapy within clinical trials and what occurs in clinical practice. I strongly caution that if TH is to be applied outside a trial, clinicians should follow published trials protocols, ensure systematic follow-up of survivors and submit patient data to national registries.
No takes yet. Share an insight, caveat, or question.
Élie Saliba (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: